VYNE Therapeutics (VYNE) Long-Term Deferred Tax (2017)

VYNE Therapeutics (VYNE) posted Long-Term Deferred Tax of $10.4 million for Q4 2017.

VYNE Therapeutics (VYNE) Long-Term Deferred Tax (2017) Analysis & Trends

VYNE Therapeutics' Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $10.4 million for Q4 2017.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $10.4 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $10.4 million (changed N/A YoY) and the FY2017 annual result came in at $10.4 million, changed N/A from the prior year.
Long-Term Deferred Tax was $10.4 million for Q4 2017 at VYNE Therapeutics.
Across five years, Long-Term Deferred Tax topped out at $10.4 million in Q4 2017 and bottomed at $10.4 million in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	VYNE Therapeutics	1.19 Bn	1.16 Bn	-

Download Data

Date	Value
Dec 31, 2017	10.40 Mn